Table 1

Sequelae among women testing positive vs negative for Trichomonas vaginalis

Among all women (n=647)
Outcome T. vaginalis (n=83)
n (%)
No T. vaginalis (n=564)
n (%)
Crude OR
(95% CI)
P valueAdjusted OR
(95% CI)
P value
Persistent endometritis at 30 days*16/52 (30.8)46/342 (13.5)2.9 (1.5 to 5.6)<0.012.6 (0.7 to 10.1)0.17
Pregnancy†40/80 (50.0)326/556 (58.6)0.7 (0.4 to 1.1)0.150.7 (0.4 to 1.1)0.14
Live birth30/32 (93.8)240/253 (94.9)0.8 (0.2 to 3.8)0.790.6 (0.1 to 3.2)0.55
Infertility‡20/80 (25.0)94/556 (16.9)1.6 (0.9 to 2.8)0.081.6 (0.9 to 3.0)0.11
Recurrent PID§19/77 (24.7)118/539 (21.9)1.2 (0.7 to 2.0)0.581.2 (0.7 to 2.1)0.62
In the subgroup of women without upper or lower tract Chlamydia trachomatis, Neisseria gonorrhoeae or Mycoplasma genitalium (n=384)
Outcome T. vaginalis (n=42)
n (%)
No T. vaginalis (n=342)
n (%)
Crude OR
(95% CI)
P valueAdjusted OR
(95% CI)
P value
Persistent endometritis at 30 days*2/27 (7.4)10/196 (5.1)1.5 (0.3 to 7.2)0.621.2 (0.2 to 6.3)0.81
Pregnancy†14/40 (35.0)185/338 (54.7)0.4 (0.2 to 0.9)0.020.5 (0.2 to 1.0)0.05
Live birth10/12 (83.3)140/149 (94.0)0.3 (0.1 to 1.7)0.180.3 (0.1 to 2.0)0.23
Infertility‡12/40 (30.0)62/338 (18.3)1.9 (0.9 to 4.0)0.081.9 (0.9 to 4.1)0.10
Recurrent PID§11/37 (29.7)69/326 (21.2)1.6 (0.7 to 3.3)0.241.4 (0.6 to 3.0)0.41
  • All models are adjusted for age, race, C. trachomatis, N. gonorrhoeae, M. genitalium and bacterial vaginosis. Pregnancy, live birth and infertility models are additionally adjusted for self-reported history of infertility at baseline, and recurrent PID models are additionally adjusted for self-reported history of PID.

  • *Persistent endometritis was defined as the presence of acute histological endometritis (≥5 neutrophils and ≥1 plasma cell) at both baseline and 30-day clinic visits.

  • †Pregnancy was defined by a physician diagnosis or positive blood or urine β-hCG test.

  • ‡Infertility was defined as a lack of conception despite 12 or more months of unprotected intercourse or inconsistent contraceptive use.

  • §Recurrent PID was defined as self-report of one or more episodes of PID during follow-up and was verified by medical record review where possible.

  • β-hCG, human chorionic gonadotropin; PID, pelvic inflammatory disease.